Safety and Efficacy of Edaravone in Patients with Amyotrophic Lateral Sclerosis: A Systematic Review and Meta-analysis

ConclusionsCompared with placebo, edaravone may provide potential clinical benefits in the treatment of ALS and may not increase the number of AEs and deaths. However, due to the low-quality evidence of the included studies and the small sample size, more high-quality and high-standard research evidence is needed to confirm these results.Protocol RegistrationThis study was registered on PROSPERO (ID: CRD 42022319997).
Source: Clinical Drug Investigation - Category: Drugs & Pharmacology Source Type: research